WMCC

Home/WMCC

About WMCC

This author has not yet filled in any details.
So far WMCC has created 44 blog entries.

Gastrointestinal System

A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair. (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer) EA2142: Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic [...]

Gastrointestinal System2020-02-20T10:59:38-04:00

Genitourinary System

A031102: A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors – MALE GENDER ONLY. A031501: Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muScle [...]

Genitourinary System2020-02-04T08:24:58-04:00

Gynecologic

EAY131 (MATCH): Molecular Analysis for Therapy Choice GOG 0238: A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus GOG 0263: Randomized phase III clinical trial of adjuvant radiation vs. chemoradiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy [...]

Gynecologic2020-02-04T08:21:55-04:00

Breast

A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL) A011502: A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive, HER2 Negative Breast Cancer: The Aspirin for Breast Cancer Study (ABC Study) A171601: A Phase II [...]

Breast2020-01-27T10:33:19-04:00

Head & Neck

EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA RTOG 1008: A Randomized Phase II Study of Adjuvant Concurrent [...]

Head & Neck2020-01-13T09:53:08-04:00

Sarcomas

No Clinical Trials Available

Sarcomas2020-01-13T11:05:06-04:00

Myeloma

A061202: A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy (Presently in Phase II)  

Myeloma2020-01-13T10:58:27-04:00

Lymphoma

Dana Farber: 14-174: Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome S1608: Randomized Phase II Study in Early Relapsing or Refractory Follicular Lymphoma S1826:  A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with [...]

Lymphoma2020-01-13T10:49:10-04:00

Lung

A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer; Crizotinib Versus Placebo for [...]

Lung2020-01-13T11:03:22-04:00

Melanoma

EA6134: A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression versus Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma S1616: Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 [...]

Melanoma2020-01-13T11:04:40-04:00